This announcement is a separate document:
复旦张江自愿披露关于注射用FDA018抗体偶联剂用于治疗三阴性乳腺癌Ⅲ期临床试验完成首例受试者入组的公告
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. voluntarily discloses the announcement of the completion of the first subject enrollment in the phase III clinical trial of injection FDA018 antibody conjugate for the treatment of triple-negative breast cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.